What is Ypsomed's ticker symbol?
Ypsomed Holding AG is publicly traded on the SIX Swiss Exchange under the official ticker symbol YPSN. As a leading developer and manufacturer of injection and infusion systems for self-medication—such as insulin pens and automatic injection devices—the company's shares are closely tracked by institutional investors and healthcare analysts monitoring medical technology advancements, device manufacturing output, and global biopharmaceutical delivery system trends across European equity markets.
Related FAQs
YTL Corporation Berhad operates as a massive multinational conglomerate headquartered in Malaysia, generating its highly diversified revenues through multiple core business segments spanning utilities, construction, cement manufacturing, property dev...
Purchasing an insulin pump entirely out-of-pocket without insurance coverage is exceptionally expensive due to specialized medical device regulations and proprietary technology costs, with upfront device prices typically running several thousand doll...
Ypsomed Holding AG maintains a strong gross profit margin hovering around 43.0%, reflecting efficient production and distribution economics within its advanced medical device and self-injection systems segments.
As of the week starting July 20, 2026, market analysts have highlighted several stocks for potential consideration.
Intuitive Machines, Inc. is a diversified space exploration, infrastructure, and technology company providing lunar access services, spacecraft design, lunar data transmission systems, and specialized orbital support.
The automated insulin delivery landscape features advanced closed-loop systems that integrate continuous glucose monitors to optimize diabetes care.
Australia's financial sector and insurance market comprise a diverse array of regulated entities operating across life insurance, general insurance, and private health insurance sectors.
Yes, Ypsomed Holding AG operates as a publicly traded enterprise, with its shares listed on the SIX Swiss Exchange under the ticker symbol YPSN.
Ypsomed Holding AG operates as a prominent Swiss multinational medical technology enterprise that specializes in the design, development, and manufacturing of innovative injection and infusion systems for self-medication.
Endocrinology and diabetes care professionals frequently identify diabetic ketoacidosis (DKA) as the most serious, life-threatening potential complication associated with continuous insulin pump therapy.
Advanced automated insulin delivery systems and integrated continuous glucose-monitoring hybrid closed-loop pumps—such as the Tandem t:slim X2 or Medtronic advanced pump series—represent some of the most expensive durable medical equipment options fo...
Overall retail and out-of-pocket costs for essential insulin have largely stabilized or decreased for many patients due to widespread manufacturer copay caps, legislative pricing reforms, and expanding biosimilar competition, though broad pharmaceuti...
Ypsomed Holding AG enjoys strong long-term growth prospects driven by rising global prevalence of chronic conditions like diabetes and obesity, alongside accelerating demand for self-injection systems and connected medical devices.
Generating a steady passive income stream of 1,000 US dollars per month (totaling 12,000 US dollars annually) entirely through dividend-paying stocks or exchange-traded funds requires calculating the portfolio size against prevailing average dividend...
Market sentiment among healthcare equity analysts frequently leans toward a buy recommendation for Ypsomed stock, driven by strong structural demand for self-injection devices, smart insulin pens, and chronic disease management tools.